{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:47:24Z","timestamp":1793908044737,"version":"4.8.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.1001\/jamacardio.2020.2314","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T11:02:06Z","timestamp":1593601326000},"page":"1124","source":"Crossref","is-referenced-by-count":172,"title":["Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia"],"prefix":"10.1001","volume":"5","author":[{"given":"Maciej","family":"Banach","sequence":"first","affiliation":[{"name":"Department of Hypertension, Medical University of \u0141\u00f3d\u017a, \u0141\u00f3d\u017a, Poland"},{"name":"Polish Mother\u2019s Memorial Hospital Research Institute, \u0141\u00f3d\u017a, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Barton","family":"Duell","sequence":"additional","affiliation":[{"name":"Knight Cardiovascular Institute, School of Medicine, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Antonio M.","family":"Gotto","sequence":"additional","affiliation":[{"name":"Cardiovascular Unit, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[{"name":"Clinic and Polyclinic for Cardiology, Leipzig University, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute, St Michael\u2019s Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. B. John","family":"Mancini","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Public Health, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Flaim","sequence":"additional","affiliation":[{"name":"Esperion Therapeutics Inc, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Ye","sequence":"additional","affiliation":[{"name":"Esperion Therapeutics Inc, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[{"name":"Department of Pharmacological and Biomolecular Sciences, University of Milan and IRCCS Multimedica, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9753","key":"hoi200039r1","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"23","key":"hoi200039r2","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1056\/NEJMsa053935","article-title":"Explaining the decrease in U.S. deaths from coronary disease, 1980-2000.","volume":"356","author":"Ford","year":"2007","journal-title":"N Engl J Med"},{"key":"hoi200039r3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12916-016-0550-5","article-title":"Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? a pro\/con debate.","volume":"14","author":"Hobbs","year":"2016","journal-title":"BMC Med"},{"issue":"2","key":"hoi200039r4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2014full report.","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"5","key":"hoi200039r5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"hoi200039r6","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-Up.","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hoi200039r7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013851","article-title":"Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study.","volume":"7","author":"Danese","year":"2017","journal-title":"BMJ Open"},{"issue":"10","key":"hoi200039r8","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","article-title":"Optimizing cholesterol treatment in patients with muscle complaints.","volume":"70","author":"Rosenson","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi200039r9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance\u2014an attempt at a unified definition: position paper from an international lipid expert panel.","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"issue":"7","key":"hoi200039r10","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group update (2016).","volume":"32","author":"Mancini","year":"2016","journal-title":"Can J Cardiol"},{"key":"hoi200039r11","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"hoi200039r12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study.","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"issue":"11","key":"hoi200039r13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol.","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"hoi200039r14","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and Safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance.","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"hoi200039r15","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial.","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"issue":"20","key":"hoi200039r16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"hoi200039r20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1056\/NEJMc1311039","article-title":"Safety profile of extended-release niacin in the AIM-HIGH trial.","volume":"371","author":"Anderson","year":"2014","journal-title":"N Engl J Med"},{"key":"hoi200039r22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-319-33943-6","article-title":"Tendon homeostasis in hypercholesterolemia.","volume":"920","author":"Soslowsky","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"hoi200039r23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11926-017-0704-2","article-title":"Tendon pathology in hypercholesterolemia and familial hypercholesterolemia.","volume":"19","author":"Taylor","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"hoi200039r24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jot.2018.07.003","article-title":"Tendon pathology in hypercholesterolaemia patients: epidemiology, pathogenesis and management.","volume":"16","author":"Yang","year":"2018","journal-title":"J Orthop Translat"},{"issue":"4","key":"hoi200039r26","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jacc.2019.11.030","article-title":"Sustained low-density lipoprotein cholesterol lowering with alirocumab in ODYSSEY OUTCOMES.","volume":"75","author":"Goodman","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi200039r27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","article-title":"Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER).","volume":"105","author":"Nicholls","year":"2010","journal-title":"Am J Cardiol"},{"issue":"6","key":"hoi200039r28","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"24","key":"hoi200039r30","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi200039r31","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jacl.2017.04.120","article-title":"Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: results of a healthcare provider survey conducted by the National Lipid Association.","volume":"11","author":"Cohen","year":"2017","journal-title":"J Clin Lipidol"},{"key":"hoi200039r17","year":"2020"},{"key":"hoi200039r18","year":"2016"},{"key":"hoi200039r19","year":"1996"},{"key":"hoi200039r25","year":"2002"},{"key":"hoi200039r21","unstructured":"ClinicalTrials.gov. Long-term safety and tolerability of alirocumab (SAR236553\/REGN727) versus placebo on top of lipid-modifying therapy in high cardiovascular risk patients with hypercholesterolemia (ODYSSEY Long Term). Accessed March 25, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01507831"},{"key":"hoi200039r29","unstructured":"US National Library of Medicine. Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes). ClinicalTrials.gov Identifier: NCT02993406. Accessed May 20, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02993406"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2767760\/jamacardiology_banach_2020_oi_200039_1602688126.22258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T11:01:57Z","timestamp":1603278117000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2767760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2020.2314","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}